What is MiniMed Group 's R&D?

MiniMed Group (MMED) reported R&D of $114M in Q1 2026.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

MiniMed Group MMED R&D

R&D at other companies

RepligenRGEN

$14.46M+19.3%

Sensata TechnologiesST

$31.9M-13.3%

AppFolioAPPF

$49.63M+13.4%

SynapticsSYNA

$94.5M+6.7%

TFX

TeleflexTFX

$44.39M+75.5%

Silicon LaboratoriesSLAB

$88.59M+0.4%

Other financials

Income statement

See full

Revenue$790.0M+15.0%

Gross profit$362.0M-8.4%

Operating income-$100.0M-576%

Net income-$119.0M-1,090%

EPS (diluted)-$0.47-1,075%

Balance sheet

See full

Cash & equivalents$10.0M0.0%

Total debt$61.0M—

Total equity$3.5B-0.7%

Total assets$4.3B—

Cash flow

See full

Operating cash flow-$27.0M-147%

CapEx$167.0M+22.8%

Free cash flow-$194.0M-146%

Valuation

See full

Market cap$3.86B—

Returns & leverage

See full

Debt / equity0×—

Current ratio1.6×—

Where this comes from

Reported directly by MiniMed Group in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: MiniMed Group ’s 10-Q, filed April 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiniMed Group 's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MiniMed Group 's R&D?: MiniMed Group (MMED) reported R&D of $114M in Q1 2026.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.